Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Advanced Solid Tumors 3Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Solid Tumors 1Solid Malignancies 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Glioma 1

Interventions

Temozolomide 32Radiotherapy 11Bevacizumab 10Surgical Procedures, Operative 7IL13-PE38 7TIC10 compound 6Lomustine 6Carboplatin 6Radiation 5Chlorotoxin 5vorasidenib 4trametinib 4dabrafenib 4Valacyclovir 4OKN 007 4Flucytosine 4Dianhydrogalactitol 4Cyclophosphamide 4vocimagene amiretrorepvec 3abemaciclib 3Paclitaxel 3Nivolumab 3Irinotecan 3Granulocyte-Macrophage Colony-Stimulating Factor 3CLR1404 3trans-sodium crocetinate 2pembrolizumab 2olutasidenib 2marizomib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Glioma × ST 1481 × Clear all
NCT00032903 2009-06-03

This is an Early Study to Investigate the Effect of GimatecanĀ® in Adults With Malignant Glioma.

Sigma-Tau Research, Inc.

Phase 1/2 Completed
59 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚔